JNJ vs LLY
Johnson & Johnson and Eli Lilly, both Healthcare
Eli Lilly is the larger company at $1.2T against $635B. On trailing earnings JNJ is the cheaper of the two at a P/E of 40.0 against 42.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year LLY returned +56% against +40% for JNJ. The RyuScore puts JNJ ahead, 68 against 60 out of 100.
| Figure | JNJ | LLY |
|---|---|---|
| Last close | $264 | $1274 |
| Market cap | $635B | $1.2T |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 40.0 | 42.8 |
| Dividend yield | 2.0% | 0.5% |
| 1-year return | +40% | +56% |
| 5-year return | +88% | +470% |
| RyuScoresector-relative, 1–10 | 68/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Johnson & Johnson
Revenue of $25B in Q3 2026, net income $210M. Its largest reported line is DARZALEX, 19% of the disclosed total.
Eli Lilly
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.